Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating in a note issued to investors on Friday, Marketbeat Ratings reports. They presently have a $2.00 price objective on the stock, down from their prior price objective of $6.00. Stifel Nicolaus' price objective suggests a potential upside of 39.86% from the stock's current price.
A number of other analysts also recently commented on NMRA. Bank of America decreased their target price on Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics currently has a consensus rating of "Hold" and an average target price of $10.14.
Read Our Latest Report on Neumora Therapeutics
Neumora Therapeutics Stock Performance
Neumora Therapeutics stock traded up $0.09 during trading hours on Friday, reaching $1.43. 1,227,622 shares of the stock were exchanged, compared to its average volume of 1,422,371. The firm's 50 day moving average is $2.24 and its 200 day moving average is $8.52. The stock has a market cap of $231.63 million, a P/E ratio of -0.76 and a beta of 2.59. Neumora Therapeutics has a 52-week low of $1.26 and a 52-week high of $18.61.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. Equities research analysts expect that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company's stock valued at $26,159,000 after buying an additional 694,385 shares during the last quarter. Barclays PLC lifted its holdings in shares of Neumora Therapeutics by 352.9% in the 3rd quarter. Barclays PLC now owns 129,210 shares of the company's stock worth $1,708,000 after purchasing an additional 100,678 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after buying an additional 406,891 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Neumora Therapeutics in the third quarter valued at $1,097,000. Finally, Wexford Capital LP lifted its stake in Neumora Therapeutics by 90.1% in the third quarter. Wexford Capital LP now owns 217,879 shares of the company's stock valued at $2,878,000 after buying an additional 103,285 shares during the last quarter. Institutional investors own 47.65% of the company's stock.
Neumora Therapeutics Company Profile
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
